RU2014140336A - Иммунологически полезные соли аргинина - Google Patents
Иммунологически полезные соли аргинина Download PDFInfo
- Publication number
- RU2014140336A RU2014140336A RU2014140336A RU2014140336A RU2014140336A RU 2014140336 A RU2014140336 A RU 2014140336A RU 2014140336 A RU2014140336 A RU 2014140336A RU 2014140336 A RU2014140336 A RU 2014140336A RU 2014140336 A RU2014140336 A RU 2014140336A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- ethoxy
- arginine
- phosphonoethoxy
- phenethyl
- Prior art date
Links
- 150000001483 arginine derivatives Chemical class 0.000 title claims abstract 11
- 150000003839 salts Chemical class 0.000 claims abstract 36
- FEMXQTNILSJYNG-UHFFFAOYSA-N 3-[5-amino-2-[2-[2-methyl-4-[2-[2-(2-phosphonoethoxy)ethoxy]ethoxy]phenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid Chemical compound CC1=CC(OCCOCCOCCP(O)(O)=O)=CC=C1CCC1=CN=C(C(N)=NC=2C3=CC=C(CCC(O)=O)C=2)C3=C1 FEMXQTNILSJYNG-UHFFFAOYSA-N 0.000 claims abstract 7
- 239000004475 Arginine Substances 0.000 claims abstract 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract 6
- 235000009697 arginine Nutrition 0.000 claims abstract 6
- 239000002184 metal Substances 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract 6
- -1 2-methyl-4- (2- (2- (2-phosphonoethoxy) ethoxy) ethoxy) phenethyl Chemical group 0.000 claims abstract 4
- 150000001875 compounds Chemical class 0.000 claims abstract 4
- 230000028993 immune response Effects 0.000 claims abstract 4
- 125000005605 benzo group Chemical group 0.000 claims abstract 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract 3
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 claims abstract 3
- 235000019260 propionic acid Nutrition 0.000 claims abstract 3
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims abstract 2
- 239000002253 acid Substances 0.000 claims abstract 2
- 239000002671 adjuvant Substances 0.000 claims abstract 2
- 230000002163 immunogen Effects 0.000 claims abstract 2
- 230000003993 interaction Effects 0.000 claims abstract 2
- 229940126601 medicinal product Drugs 0.000 claims abstract 2
- 150000004682 monohydrates Chemical group 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims abstract 2
- 239000002904 solvent Substances 0.000 claims abstract 2
- 229930064664 L-arginine Natural products 0.000 claims 1
- 235000014852 L-arginine Nutrition 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608011P | 2012-03-07 | 2012-03-07 | |
| US61/608,011 | 2012-03-07 | ||
| PCT/EP2013/054548 WO2013131985A1 (en) | 2012-03-07 | 2013-03-07 | Immunologically useful arginine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014140336A true RU2014140336A (ru) | 2016-04-27 |
Family
ID=47843276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014140336A RU2014140336A (ru) | 2012-03-07 | 2013-03-07 | Иммунологически полезные соли аргинина |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9320748B2 (enExample) |
| EP (1) | EP2822947B1 (enExample) |
| JP (1) | JP6325986B2 (enExample) |
| CN (1) | CN104203946B (enExample) |
| AU (1) | AU2013229466A1 (enExample) |
| CA (1) | CA2865759C (enExample) |
| CY (1) | CY1118091T1 (enExample) |
| DK (1) | DK2822947T3 (enExample) |
| ES (1) | ES2597755T3 (enExample) |
| HR (1) | HRP20161354T1 (enExample) |
| HU (1) | HUE030175T2 (enExample) |
| LT (1) | LT2822947T (enExample) |
| MX (1) | MX346678B (enExample) |
| PL (1) | PL2822947T3 (enExample) |
| PT (1) | PT2822947T (enExample) |
| RU (1) | RU2014140336A (enExample) |
| SI (1) | SI2822947T1 (enExample) |
| WO (1) | WO2013131985A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| US9375471B2 (en) | 2012-03-08 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Adjuvanted formulations of booster vaccines |
| EP3122378B1 (en) | 2014-03-26 | 2019-12-11 | GlaxoSmithKline Biologicals S.A. | Mutant staphylococcal antigens |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| EP4114463A4 (en) * | 2020-03-01 | 2023-09-06 | Dynavax Technologies Corporation | CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST |
| WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| GB202215414D0 (en) | 2022-10-18 | 2022-11-30 | Glaxosmithkline Biologicals Sa | Vaccine |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6699474B1 (en) | 1990-08-20 | 2004-03-02 | Erich Hugo Cerny | Vaccine and immunserum against drugs of abuse |
| WO1993018150A1 (en) | 1992-03-02 | 1993-09-16 | Biocine S.P.A. | Helicobacter pylori proteins useful for vaccines and diagnostics |
| FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
| JPH10502365A (ja) | 1994-07-01 | 1998-03-03 | リカン・リミテッド | ヘリコバクタータンパク質およびワクチン |
| GB2324093A (en) | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| ATE440861T1 (de) | 2000-07-03 | 2009-09-15 | Novartis Vaccines & Diagnostic | Immunisierung gegen chlamydia pneumoniae |
| FR2827605B1 (fr) | 2001-07-20 | 2004-07-16 | Pf Medicament | Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin |
| ES2312649T3 (es) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | Inmunizacion frente a chlamydia trachomatis. |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| DE60335477D1 (de) | 2002-10-11 | 2011-02-03 | Novartis Vaccines & Diagnostic | Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien |
| JP4896715B2 (ja) | 2003-06-26 | 2012-03-14 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫原性組成物 |
| RU2006134631A (ru) | 2004-03-02 | 2008-04-10 | Чирон Корпорейшн (Us) | Иммуногенные композиции против chlamidia pneumoniae |
| ES2595363T3 (es) | 2005-02-18 | 2016-12-29 | J. Craig Venter Institute, Inc. | Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli |
| US8062644B2 (en) | 2005-02-18 | 2011-11-22 | Novartis Vaccines & Diagnostics Srl. | Immunogens from uropathogenic Escherichia coli |
| EP1891096A2 (en) | 2005-05-12 | 2008-02-27 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions for chlamydia trachomatis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| EP1976557A2 (en) | 2005-12-22 | 2008-10-08 | Novartis Vaccines and Diagnostics S.r.l. | Chlamydial antigens |
| WO2008020330A2 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
| NZ584683A (en) | 2007-10-19 | 2012-05-25 | Novartis Ag | Neisseria meningitidis serogroup B vaccine formulations |
| CA2758490C (en) | 2009-04-14 | 2023-05-02 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| ES2531115T3 (es) | 2009-06-01 | 2015-03-10 | Novartis Ag | Combinaciones de clados de RrgB neumocócicos |
| CN102762226A (zh) * | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
| BR112012004275A2 (pt) | 2009-08-27 | 2016-11-16 | Novartis Ag | polipeptídios híbridos incluindo sequências meningocócicas de fhbp |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| CN105999275A (zh) | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| EP2667852B1 (en) | 2011-01-27 | 2016-11-09 | GlaxoSmithKline Biologicals SA | Adjuvant nanoemulsions with crystallisation inhibitors |
| KR20140066212A (ko) * | 2011-09-01 | 2014-05-30 | 노파르티스 아게 | 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물 |
-
2013
- 2013-03-07 HR HRP20161354TT patent/HRP20161354T1/hr unknown
- 2013-03-07 PT PT137081428T patent/PT2822947T/pt unknown
- 2013-03-07 PL PL13708142T patent/PL2822947T3/pl unknown
- 2013-03-07 EP EP13708142.8A patent/EP2822947B1/en active Active
- 2013-03-07 MX MX2014010423A patent/MX346678B/es active IP Right Grant
- 2013-03-07 HU HUE13708142A patent/HUE030175T2/en unknown
- 2013-03-07 CN CN201380012851.1A patent/CN104203946B/zh active Active
- 2013-03-07 RU RU2014140336A patent/RU2014140336A/ru not_active Application Discontinuation
- 2013-03-07 DK DK13708142.8T patent/DK2822947T3/en active
- 2013-03-07 SI SI201330288A patent/SI2822947T1/sl unknown
- 2013-03-07 ES ES13708142.8T patent/ES2597755T3/es active Active
- 2013-03-07 CA CA2865759A patent/CA2865759C/en active Active
- 2013-03-07 LT LTEP13708142.8T patent/LT2822947T/lt unknown
- 2013-03-07 US US14/381,513 patent/US9320748B2/en active Active
- 2013-03-07 WO PCT/EP2013/054548 patent/WO2013131985A1/en not_active Ceased
- 2013-03-07 AU AU2013229466A patent/AU2013229466A1/en not_active Abandoned
- 2013-03-07 JP JP2014560367A patent/JP6325986B2/ja active Active
-
2016
- 2016-10-10 CY CY20161101006T patent/CY1118091T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2597755T3 (es) | 2017-01-20 |
| EP2822947B1 (en) | 2016-08-03 |
| CN104203946A (zh) | 2014-12-10 |
| AU2013229466A1 (en) | 2014-09-04 |
| PT2822947T (pt) | 2016-09-26 |
| MX346678B (es) | 2017-03-29 |
| US20150125475A1 (en) | 2015-05-07 |
| US9320748B2 (en) | 2016-04-26 |
| JP2015511957A (ja) | 2015-04-23 |
| DK2822947T3 (en) | 2016-09-19 |
| LT2822947T (lt) | 2016-10-10 |
| HRP20161354T1 (hr) | 2016-12-02 |
| EP2822947A1 (en) | 2015-01-14 |
| CN104203946B (zh) | 2017-03-22 |
| CA2865759A1 (en) | 2013-09-12 |
| PL2822947T3 (pl) | 2017-01-31 |
| JP6325986B2 (ja) | 2018-05-16 |
| CY1118091T1 (el) | 2017-06-28 |
| HUE030175T2 (en) | 2017-04-28 |
| WO2013131985A1 (en) | 2013-09-12 |
| MX2014010423A (es) | 2014-09-22 |
| CA2865759C (en) | 2020-07-21 |
| SI2822947T1 (sl) | 2016-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014140336A (ru) | Иммунологически полезные соли аргинина | |
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201390840A1 (ru) | Полициклический lpaантагонист и его применение | |
| HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
| RU2015117251A (ru) | Новые соединения | |
| IN2014MN01755A (enExample) | ||
| JP2015511957A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| EA201490569A1 (ru) | Полиморфная форма гидрохлорида придопидина | |
| JP2016526024A5 (enExample) | ||
| MX383762B (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
| PH12015502429A1 (en) | Dicarboxylic acid compound | |
| TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
| EA201300423A1 (ru) | Кристаллический конъюгат налоксол-peg | |
| UA105425C2 (ru) | Кристаллическая форма агомелатина гидрохлорида гидрата и способ ее получения | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
| EA201590475A1 (ru) | Тетрациклиновые соединения | |
| WO2013128419A3 (en) | Pharmaceutical compositions comprising boronic acid compounds | |
| EA201201293A1 (ru) | Гидрат гидробромида агомелатина и его получение | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| PE20131327A1 (es) | Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen | |
| AR087346A1 (es) | Formulaciones de compuestos de tiofeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170414 |